Study of MK0869 for the Prevention of Chemotherapy-Induced Nausea and Vomiting (0869-071)(COMPLETED)
The purpose of this study is to determine the efficacy and tolerability of an investigational drug for the prevention of chemotherapy-induced nausea and vomiting associated with moderately emetogenic chemotherapy.
Nausea|Vomiting|Breast Neoplasms
DRUG: MK0869, aprepitant / Duration of Treatment: 3 days
Safety and tolerability
Assessment of adverse experiences using the National Cancer Institute (NCI) criteria
The purpose of this study is to determine the efficacy and tolerability of an investigational drug for the prevention of chemotherapy-induced nausea and vomiting associated with moderately emetogenic chemotherapy.